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Abstract 34 
Although vital to the immune system, macrophages can act as reservoirs for 35 
pathogens such as tuberculosis and human immunodeficiency virus. Limitations in the 36 
treatment of such diseases include targeting therapeutics directly to macrophages and the 37 
large systemic dosages needed. The objective of this study is to develop a nanoparticle 38 
(NP)-based drug delivery system that can provide targeted delivery into macrophages. 39 
Acetalated dextran (Ac-Dex) NP loaded with the lipophilic model compound curcumin 40 
(CUR) were synthesized and coated in 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine 41 
(DPPS), a phospholipid that induces phagocytosis in macrophages. DPPS-CUR NP were 42 
found to release 67.8% of encapsulated CUR within 24 hours at pH 5.35 and exhibited 43 
minimal CUR release (6.3%) at pH 7.4. DPPS-CUR NP were uptaken by murine 44 
macrophages significantly more than NP without DPPS coating and NP exposure to these 45 
macrophages resulted in minimal toxicity to the cells and minimal nitric oxide production. 46 
These results suggest that the combination of the DPPS coating and pH-sensitive polymer 47 
Ac-Dex can provide a NP delivery system capable of enhanced uptake by macrophages 48 
and potential systemic stability to more effectively deliver drugs of interest. As a result, 49 
the described DPPS-CUR NP can serve as a viable delivery system for the treatment of 50 
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Introduction 74 
Macrophages are vital in the removal of cellular debris and foreign bodies to 75 
maintain homeostasis in the human body [1,2], can colonize in the liver, lungs, spleen, 76 
lymph nodes, marrow, or brain, and are critical to the innate immune system [2]. An 77 
example of the importance of macrophages is in the removal of apoptotic cells via 78 
stimulation of various signals and markers that are overexpressed by presenting cells to 79 
initiate identification and engulfment [3]. Although macrophages are involved in the 80 
protection and maintenance of the human body, there are scenarios in which these cells can 81 
result in more harm than good. Macrophages have the potential to act as reservoirs for 82 
infectious pathogens, including those related to two of the most prevalent infectious 83 
diseases, tuberculosis (TB) [1,2] and the human immunodeficiency virus (HIV) [1,2]. The 84 
commonality amongst these diseases lies in the extensive treatment times and dosing 85 
regimens necessary to treat TB and HIV, often resulting in negative side effects. As a result, 86 
treatment by way of enhanced delivery to macrophages is of growing interest [1–17]. 87 
Recent progress made in the development of macrophage targeting systems have 88 
been based around receptor-ligand interactions [18]. One common approach is surface 89 
functionalization of particle systems with mannose residues to target the mannose receptor 90 
CD206), a carbohydrate-recognition domain that is largely expressed on alveolar 91 
macrophages [19,20]. In other cases, tumor associated macrophages have been targeted 92 
using peptide-based ligands such as rabies virus glycoprotein (RVG), and can be used as 93 
carriers for systems encapsulating anti-cancer therapies [21,22]. Other ligands such as 4-94 
SO4-GalNAc have been used to target other receptors on the surface of phagocytic 95 
macrophages to increase targeted uptake [23].  96 
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Phosphatidylserine (PS) is an anionic phospholipid that is produced and stationed 97 
on the inner membrane of healthy cells [3,5,24,25]. Once apoptosis is induced, PS 98 
transitions from the inner leaflet to the outer leaflet of the cell membrane [14]. Apoptotic 99 
cells produce a signal via PS exposure to stimulate the attraction of macrophages for 100 
engulfment of the presenting cells (phagocytosis) via receptor-ligand interactions or 101 
identification of PS binding proteins produced by phagocytes [1,3,25,26]. Although it is 102 
essential for the phagocytosis signal, there is some debate as to whether sole exposure of 103 
PS is sufficient to induce the uptake of apoptotic cells by macrophages in vitro [3,25,26]. 104 
However, particle-based drug delivery systems that utilize PS (specifically, 1,2-105 
dipalmitoyl-sn-glycero-3-phospho-L-serine, DPPS) as the particle coating have resulted in 106 
enhanced macrophage uptake through the sole presence of PS [3], likely due to the amount 107 
of PS presented. Multiple studies centered around treatment of inflammation [7,27], HIV-108 
1 [1,2,6,17], cancer [8,9,28], atherosclerosis [29], and MRI imaging [1,11,16] have used 109 
DPPS coatings to increase the uptake of particle-based delivery systems by macrophages 110 
or have used PS as a binding target.  111 
Acetalated dextran (Ac-Dex) is a biodegradable, biocompatible polymer comprised 112 
of the FDA-approved excipient dextran and hydrophobic acetal groups that allow for 113 
emulsion-based NP synthesis [30–32]. Unlike commonly used drug carriers such as 114 
poly(lactic-co-glycolic acid) (PLGA), the degradation kinetics of Ac-Dex can be easily 115 
tuned by altering the ratio of cyclic to acyclic acetal groups by modifying the Ac-Dex 116 
synthesis reaction time [33,34]. The acid-sensitivity of Ac-Dex has made it a viable carrier 117 
option in applications for cancer [33–35], inflammatory-related conditions [36], vaccines 118 
[33,34], and antibiotic delivery [37]. There is a significant difference in degradation and 119 
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drug release kinetics for Ac-Dex nanoparticle (NP) systems at a pH of 5 (faster release) 120 
versus at a pH of 7.4 (slower release) [4,30,31,33–37]. Due to this difference, Ac-Dex NP 121 
systems will exhibit slower release and stability during systemic circulation (at pH 7.4) 122 
until they are delivered to a site in the body with a lower pH, such as in macrophages, 123 
where therapeutics will be readily released. 124 
 The current study involves the design of a novel therapeutic particle-based drug 125 
delivery system consisting of a phosphatidylserine (PS)-coated, polymeric (Ac-Dex), drug-126 
loaded NP designed to enhance uptake into macrophages. The novelty of this formulation 127 
lies in the inherent ability of PS to enhance the uptake of the NP into macrophages, while 128 
the Ac-Dex core promotes burst release of the cargo directly in the macrophages owing to 129 
its acid sensitivity. Curcumin (CUR), a natural product isolated from Curcuma longa, was 130 
chosen as the model small molecule due to its fluorescent properties, low water solubility, 131 
and potential clinical applications [4,5,7,9,13,30,38–42].  132 
 133 
Materials and Methods 134 
 135 
Materials 136 
Unless stated otherwise, materials were purchased from Sigma Aldrich (St. Louis, 137 
MO). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-138 
3-phospho(1’-rac’glycerol) (DPPG), and 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine 139 
(sodium salt, DPPS) were purchased from Avanti Lipids (Alabaster, AL).  140 
 141 
Synthesis and Characterization of Acetalated Dextran 142 
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Acetalated dextran (Ac-Dex) was synthesized using a previously described method 143 
[30,31]. 1 g of lyophilized dextran (9,000-11,000 MW) was dissolved in 10 mL of 144 
anhydrous DMSO with 25 mg of p-toluenesulfonate (PPTS) under nitrogen gas. The 145 
reaction was carried out for 5 minutes using 5 mL of 2-methoxypropene (2-MOP) and was 146 
quenched with 1 mL of triethylamine (TEA). The polymer was then precipitated in basic 147 
water (pH 9), filtered, lyophilized, and stored at -20C. The cyclic-to-acyclic (CAC) ratio 148 
of Ac-Dex and acetal coverage were verified using 1H NMR (Bruker 300 MHz, NMR, 149 
MA) as described previously [30,31,37].   150 
 151 
Synthesis of PVA-Coated Nanoparticles  152 
PVA-coated, CUR-loaded Ac-Dex NP (PVA-CUR NP) were synthesized using a 153 
single emulsion/solvent evaporation method [31]. 50 mg of Ac-Dex and 1 mg of CUR were 154 
dissolved in 1 mL of DCM. This organic solution was added to 6 mL of 3% PVA (in 1x 155 
PBS) and the resulting mixture was emulsified using a probe sonicator attached to an 156 
ultrasonic processer at 120 W and 20 kHz (Q500, Qsonica, Newtown, CT) for 1 minute 157 
with 1 second on/off pulses. The emulsion was added to 40 mL of 0.3% PVA and was spun 158 
for 4 hours to allow for organic solvent evaporation and particle hardening [30]. The 159 
spinning solution was centrifuged at 3124 x g for 60 minutes and particles were redispersed 160 
in a 0.1% PVA solution and frozen overnight, followed by lyophilization. PVA-coated NP 161 
without CUR (PVA-Blank NP) were formulated similarly to PVA-CUR NP by omitting 162 
CUR from the organic solutions. NP samples were stored at -20C.   163 
 164 
Synthesis of DPPS and DPPC-Coated Ac-Dex NP 165 
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PVA-coated NP were coated with DPPS via a film hydration method often used to 166 
make liposomal delivery systems [6,7,17,27,43,44]. DPPS was dissolved in 4 mL of 167 
chloroform and methanol (9:1 v/v) [9]. The solution was subjected to rotary evaporation 168 
using a Heidolph 2 rotary evaporator (Schwabach, Germany) to create a thin film in a 25 169 
mL round-bottom flask. The film was dried under vacuum for 1 hour to remove excess 170 
solvent, during which the NP were washed with deionized (DI) water to remove excess 171 
PVA. The dried film containing the NP was then rehydrated with 4 mL of DI water and 172 
this solution was sonicated for 30 minutes, followed by freezing and lyophilization. After 173 
lyophilization, the resulting NP were stored at -20C. The ratio of lipid to NP during the 174 
process was 1:5 (w/w). NP coated with DPPC and a small amount of DPPG NP were 175 
synthesized using the same method with a 5:1 (w/w) DPPC:DPPG ratio and these NP are 176 
referred to as DPPC-NP.  177 
 178 
Nanoparticle Size and Surface Charge Characterization  179 
Hydrodynamic diameter and surface charge of the NP were evaluated via dynamic 180 
light scattering (DLS) and zeta potential analysis, respectively, using a Malvern Nano 181 
Zetasizer (Malvern Instruments, Worcestershire, UK). The NP were diluted to 0.25 mg/mL 182 
in DI water and were analyzed at 25C and an angle of 90.  183 
 184 
Evaluation of CUR NP Encapsulation Efficiency and Drug Loading  185 
To determine the amount of CUR encapsulated in the NP systems, NP were 186 
dissolved in DMSO (1 mg/mL) and the fluorescence of the solutions was analyzed using a 187 
SpectraMax M2 Plate Reader (Molecular Devices, Sunnyville, CA) at an excitation of 420 188 
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nm and emission of 520 nm. The encapsulation efficiency (EE) and drug loading were 189 
calculated using the following equations: 190 
 191 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐸𝐸) =  
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑁𝑃
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑁𝑃
𝑥 100% 192 
 193 
𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 =  




Electron Microscopy Imaging Analysis of Nanoparticles 196 
Images of the NP were taken using a Zeiss Sigma VP Field Emission-Scanning 197 
Electron Microscope (FE-SEM) (Germany) for analysis of NP morphology. After NP were 198 
suspended in basic water (15 mg/mL), 1-2 drops of this suspension were added to 199 
aluminum SEM stubs (TedPella Inc., Redding, CA), and the samples were air dried. Dried 200 
samples were then coated with a film of gold/palladium alloy using an Emscope SC400 201 
sputter coating system at a 20 µA for 75 seconds under argon. Images of the NP systems 202 
were also captured via a JEOL JEM-2100F transmission electron microscope (TEM, 203 
Peabody, MA) for observation of the NP core and outer layers. 1 µL of 15 mg/mL NP 204 
suspension in water were placed on 200 square mesh copper grids (Election Microscopy 205 
Sciences, Hatfield, PA) and air dried prior to imaging.  206 
 207 
Differential Scanning Calorimetry (DSC) Analysis of Nanoparticles 208 
Thermal phase transitions of the NP systems were analyzed using differential 209 
scanning calorimetry (DSC) via a TA Q10 DSC system (TA Instruments, New Castle, DE) 210 
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connected to an RSC-90 cooling accessory. For dry-state DSC, samples were lyophilized 211 
24 hours prior to analysis. 1-3 mg of NP were analyzed at 10C/min from 0 to 300C. For 212 
wet state analysis, NP were dispersed in DI water (0.1 mM DPPS) and 15 µL of the NP 213 
suspension was added to aluminum pans to be analyzed at 2C/min and from 5 to 65C. 214 
DSC analysis of the raw materials was also performed.  215 
 216 
PVA Coating Quantification 217 
Quantification of the amount of PVA on the surface of NP was completed using a 218 
previously described method [45]. NP samples were dispersed in DI water (1 mg/mL). 400 219 
µL of sample solution, 300 µL of iodine solution (1.25 % iodine and 2.5% potassium 220 
iodide), and 1.5 mL of 4% boric acid solution were mixed together for 20 minutes at room 221 
temperature and 100 rpm. Absorbance of the samples was measured at a wavelength of 222 
630 nm.  223 
 224 
Phospholipid Content Quantification 225 
 Phospholipid quantification was carried out using Stewart’s method [46]. Briefly, 226 
2.7 g ferric chloride hexahydrate and 3 g of ammonium thiocyanate was dissolved in 100 227 
mL of distilled water. NP samples were dissolved in chloroform (1 mg/mL) and were 228 
mixed with the ammonium ferrothiocyanate solution via vortexing for 5 minutes at a 2:1 229 
(v/v) ratio. After mixing, the solution was allowed to separate, and the phospholipid content 230 
in the chloroform portion was measured via UV-vis spectroscopy at 488 nm (DPPC/G) and 231 
452 nm (DPPS).  232 
 233 
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In Vitro Drug Release from CUR NP 234 
Release of CUR from the NP was carried out using a previously established 235 
centrifugation technique [30]. 1 mg/mL NP samples were dispersed in PBS (pH 7.4) or 236 
sodium acetate buffer (pH 5.35) supplemented using 0.2% Tween® 80 to enhance CUR 237 
solubility. The suspensions were incubated at 37C and 100 rpm and at predetermined time 238 
points the suspensions were removed and centrifuged at 23,102 x g for 15 minutes. 200 µL 239 
of the supernatant was collected and frozen at -20C and 200 µL of fresh medium was 240 
added to the particle solution prior to re-dispersion and re-incubation. Release samples 241 
were mixed with DMSO (1:1 by volume) prior to fluorescence spectroscopy analysis at an 242 
excitation of 420 nm and emission of 520 nm [30]. 243 
 244 
Cell Culture 245 
Murine macrophage cells (RAW 264.7) and A549 human adenocarcinoma cells 246 
obtained from American Type Culture Collection (ATCC, Manassas, VA) were used for 247 
cell culture studies. The cells were maintained at 37°C and 5% CO2 in Dulbecco’s modified 248 
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml 249 
penicillin, 100 μg/ml streptomycin, Fungizone® (0.5 µg amphotericin B, 0.41 µg/mL 250 
sodium deoxycholate), and 1 mM sodium pyruvate.  251 
 252 
In Vitro Cytotoxicity Analysis of NP 253 
The cytotoxic effect of the formulated NP on RAW 264.7 macrophages was 254 
determined using a resazurin assay. Cells were seeded in 96-well plate at 5,000 cells/well 255 
and incubated overnight at 37 °C and were then exposed to varying concentrations of PVA-256 
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CUR and DPPS-CUR NP (0.001 to 0.2 mg/ml). Untreated cells were used as negative 257 
controls. After 48 hours, resazurin solution (60 μM) was added to the cells and incubated 258 
for 3 hours. The fluorescence intensity of resorufin produced by viable cells was detected 259 
at 544 nm (excitation) and 590 nm (emission) using BioTek Cytation 3 plate reader. The 260 
relative viability of each sample was calculated by: 261 
 262 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑆𝑎𝑚𝑝𝑙𝑒 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
 𝑥 100 263 
 264 
Nitrite Analysis 265 
 A Griess assay was performed to determine nitric oxide (NO) production by 266 
macrophages. Following 48-hour incubation with varying concentrations of NP (CUR-267 
loaded and blank), 96-well plates containing the samples were centrifuged and 50 μL of 268 
the resulting supernatant was removed from each well. Griess reagents were added per 269 
manufacturer’s instructions and the absorbance was measured at 550 nm. LPS (500 270 
ng/mL), was used to promote NO production as a control.  271 
 272 
In Vitro Cellular Uptake Via Spectroscopy and Confocal Microscopy  273 
 Cellular uptake of CUR-loaded NP by RAW 264.7 and A549 cells was observed 274 
using a Cytation 3 image reader (BioTek, Winooski, VT). Cells (7,500 cells/well) were 275 
seeded in a 96-well plate and incubated overnight at 37 °C. Cells were then incubated with 276 
0.1 mg/ml of NP solutions and equal concentration of CUR for 1 and 3 hours. After 277 
incubation, the media was removed, and the cells were washed three times with 200 mM 278 
glycine to remove any unbound  NP that were not taken up by the cells. For quantification 279 
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of cellular uptake, the fluorescence of the CUR within the cells was analyzed via 280 
fluorescence spectroscopy at 420 nm (excitation) and 520 nm (emission).  281 
RAW 264.7 and A549 cells were seeded into 35 mm glass-bottom petri dishes at a 282 
concentration of 500,000 cells per dish and allowed to grow overnight. DPPS-CUR NP, 283 
DPPC-CUR NP, or PVA-CUR NP were suspended and bath sonicated in cell culture 284 
medium at 0.1 mg/mL and were then incubated with cells for 1 or 3 hours. Cells were 285 
washed 3x in PBS and incubated in fresh media containing CellMask Deep Red 286 
(Invitrogen) at 1 L/mL media for 10 minutes. Cells were then fixed with 4% 287 
paraformaldehyde for 10 minutes and rinsed 3x with PBS. Fresh PBS was added and cells 288 
were immediately imaged using a Nikon Eclipse Ti2 inverted confocal fluorescent 289 
microscope. 290 
 291 
Statistical Analysis  292 
All measurements were performed in at least triplicate. Statistical differences for in 293 
vitro cellular studies was determined using one-way or two-way ANOVA with Tukey's 294 
multiple comparisons test (GraphPad Prism version 7). For cumulative drug release, 295 
Student’s t-Test was used to determine statistical differences. A p-value of < 0.05 or lower 296 
was considered as statistically significant. Values are presented as mean ±  standard 297 
deviation.  298 
 299 
Results   300 
 301 
Characterization of Ac-Dex Polymer and Nanoparticles 302 
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Analysis of the acetal coverage and cyclic-to-acyclic (CAC) ratio of Ac-Dex 303 
following its synthesis was confirmed via NMR. The acetal coverage of Ac-Dex was 73%, 304 
whereas the CAC ratio was 45%. PVA-coated NP were synthesized using the emulsion 305 
method to create NP with an Ac-Dex polymer core and PVA coating both with and without 306 
curcumin loading (PVA-CUR NP and PVA-Blank NP, respectively). As seen in Table 1, 307 
PVA-coated NP were 260-275 nm in diameter, exhibited polydispersity index (PDI) values 308 
of 0.04, and had nearly neutral surface charges (less than -3 mV), as seen from the zeta 309 
potential values.  310 
After the synthesis of PVA-coated NP, the particles were coated with DPPS using 311 
a thin film hydration method to form DPPS-coated NP, both with and without CUR loading 312 
(DPPS-CUR NP and DPPS-Blank NP, respectively). The diameters for both the blank and 313 
CUR-loaded DPPS NP increased by approximately 75 nm in comparison to the PVA-314 
coated NP. The PDI values were low for both DPPS NP systems (less than 0.21), however, 315 
there was a substantial decrease in zeta potential, from -3 mV (PVA-coated NP) to -40 mV 316 
(DPPS-coated NP) for both blank and CUR-loaded NP systems.  317 
The encapsulation efficiency (EE) and drug loading (by mass) of CUR-loaded NP 318 
was analyzed to quantify the amount of CUR loaded in the particles. Both PVA- and DPPS-319 
coated NP exhibited EE values around 25% whereas the drug loading was 7.1 and 5.2 g 320 
CUR/mg NP for PVA-CUR NP and DPPS-CUR NP, respectively.  321 
 322 
Morphological Analysis of NP Via Electron Microscopy  323 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) 324 
were used to analyze the morphology and structure of PVA- and DPPS-coated NP loaded 325 
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with CUR. SEM micrographs indicated that PVA-CUR NP presented spherical, smooth 326 
morphology and were homogenous with respect to in size (Figure 1, top). TEM images 327 
allowed for the visualization of a thin layer around the Ac-Dex polymer core, which likely 328 
corresponds to the PVA coating. DPPS-CUR NP were fairly monodisperse with spherical, 329 
smooth morphology as seen via SEM imaging (Figure 1, bottom). TEM micrographs 330 
show a coating on the Ac-Dex NP core, likely indicating the DPPS coating on the NP.  331 
 332 
Coating Quantification 333 
The amount of PVA and total phospholipids present in the NP formulations were 334 
quantified and are presented in Figure 2. There was significantly less PVA present on the 335 
DPPS and DPPC-NP in comparison to the PVA-NP (p < 0.001 and p < 0.0001, 336 
respectively). In addition, significantly more phospholipid was present in DPPS and 337 
DPPC-NP in comparison to PVA-NP (p < 0.01).  338 
 339 
Differential Scanning Calorimetry (DSC) Thermal Analysis 340 
Figure 3 shows the thermograms of the prepared NP and their corresponding raw 341 
components in their dry states. An endothermic peak at 90C was present, indicating a 342 
bilayer phase transition for the DPPS-coated NP, which is slightly lower than the 343 
endothermic phase transition temperature of raw DPPS at 99C. An endothermic peak was 344 
present at 187C for raw PVA, whereas a broadened endothermic peak was present at 345 
195C for PVA-coated NP. Both raw CUR and Ac-Dex exhibited endothermic peaks at 346 
177C, signifying their melting points [30,31,37]. These prominent endothermic peaks 347 
were not present in the formulated NP. The shift from 177C to a broad peak at 195C for 348 
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PVA-coated NP could be due to the interaction between Ac-Dex and PVA. DPPS-coated 349 
NP exhibited a broad endothermic peak at 165C, potentially due to the removal of the 350 
PVA and the interaction between the Ac-Dex and DPPS. For wet-state DSC analysis of the 351 
formulated NP, there were no measurable peaks present for the temperature range used; 352 
curvature corresponded to the evaporation of water. 353 
 354 
In Vitro Drug Release from NP 355 
The release of CUR from the particles was analyzed at two pH values, including 356 
pH 7.4 to simulate normal physiological pH and pH 5.35 to approximate the pH in 357 
macrophages [4]. Results in Figure 4 shows that there was no significant difference in the 358 
cumulative release of CUR from PVA-coated versus DPPS-coated NP at pH 7.4 after 24 359 
hours (5.2% vs 6.3%), signifying that the NP coating played no appreciable role in affecting 360 
CUR release at this pH. However, significantly more CUR was released at pH 5.35 for 361 
both DPPS- and PVA-coated particles (67.8% and 88.8% release at pH 5.35, respectively) 362 
in comparison to pH 7.4 (p < 0.001), demonstrating the sensitivity of Ac-Dex to acidic 363 
conditions. Furthermore, when comparing DPPS- and PVA-coated NP at pH 5.35, 364 
significantly more CUR was released from NP with a PVA coating, indicating the potential 365 
influence of the DPPS layer in delaying the release of the cargo (p < 0.05).  366 
 367 
In Vitro Cytotoxicity Assay 368 
The impact of the described NP systems on macrophage toxicity was evaluated and 369 
the results are presented in Figure 5. These results indicate that the cells exhibited relative 370 
viabilities similar to the control (media only) after 48 hours of exposure to the NP systems. 371 
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Increasing the concentration of NP imparted no significant change in the viability of cells 372 
for PVA-Blank NP, DPPS-Blank NP, or PVA-CUR NP for the concentrations tested. 373 
However, for DPPS-CUR NP there was a slight but statistically significant decrease in the 374 
viability of cells at 0.2 mg/ml in comparison to the control (p < 0.05).  375 
 376 
Nitrite Analysis 377 
 Following 48-hour incubation of NP samples on cells, CUR-loaded and blank 378 
(control) NP groups produced significantly lower NO in comparison to LPS (p < 0.0001) 379 
(Figure 6). The NP groups were the same as the control group (media only) statistically, 380 
indicating little to no production of NO [47].  381 
 382 
In Vitro Cellular Uptake  383 
The cellular uptake of CUR-loaded NP was evaluated in RAW 264.7 macrophages 384 
and A549 adenocarcinoma cells for up to 3 hours as shown in Figure 6. Exploiting the 385 
fluorescent properties of CUR, the presence of CUR-loaded NP within cells can easily be 386 
detected via fluorescence imaging and spectroscopy. After 1 hour of exposure, significantly 387 
more DPPS-coated NP were uptaken by macrophages and A549 cells in comparison to 388 
PVA-coated NP, DPPC-coated NP, and raw CUR (p < 0.0001). For both cell types and all 389 
formulations, uptake was not statistically different between 1 and 3-hour exposures. In 390 
addition, significantly more NP were uptaken in RAW macrophages in comparison to 391 
A549 cells for all NP formulations. Confocal microscopy confirmed fluorescence 392 
spectroscopy quantification, showing higher fluorescence in macrophages in comparison 393 
to A549 cells, indicating increased NP uptake. In addition, more NP were uptaken in DPPS-394 
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coated NP in comparison to DPPC- and PVA-coated systems in RAW and A549 cells. 395 
Images indicate that CUR-loaded NP were primarily uptaken into the cytoplasm of 396 
macrophages, especially for DPPS-CUR NP. On the other hand, there were minimal NP 397 
located in the cytoplasm of A549 cells; instead the NP were more readily located in the 398 




Nanoparticle Design and Analysis 403 
The use of Ac-Dex as a biodegradable NP core for drug delivery can allow for a 404 
system with tunable and/or triggered degradation [32]. For the described NP systems, the 405 
acetal coverage of Ac-Dex was similar to previous studies [30,31,37], whereas the CAC 406 
ratio was slightly lower. The resulting Ac-Dex was favorable for the given application as 407 
the adequate acetal coverage imparts hydrophobicity to Ac-Dex, allowing for NP 408 
formulation and the lower CAC ratio will allow for faster drug release at acidic pH 409 
[30,31,35,37].  410 
The increase in diameter and PDI from PVA-coated NP to DPPS-coated NP is 411 
likely due to the presence of the DPPS coating around the Ac-Dex core. It has been shown 412 
that an increase in NP diameter can lead to an increase in the uptake of NP into 413 
macrophages, where particles 200 nm in diameter or greater are often subjected to a greater 414 
amount of macrophage uptake [48–50]. For this study, larger NP were desired and 415 
successfully formed (up to 350 nm for DPPS-coated NP), which was advantageous since 416 
increased macrophage uptake was an objective [4]. While DPPS-coated NP exhibited 417 
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higher PDI values then PVA-coated NP, these values were still low, indicating that all of 418 
the formulated NP systems were homogenous with respect to size.  419 
The surface charge of the NP, as indicated by zeta potential, decreased significantly 420 
(from -3 to -40 mV) upon coating with DPPS. The negative surface charge on the DPPS-421 
loaded NP is indicative of the polar head of DPPS being exposed to the outer environment, 422 
similar to how apoptotic cells present DPPS to the outer leaflet of cells prior to engulfment 423 
by macrophages [6,28]. The highly negatively surface charge is significantly lower than 424 
the -25 mV threshold of being functionally negative, indicating that the NP are less likely 425 
to aggregate due to electrostatic repulsion [51,52]. It should be noted that DPPC-coated NP 426 
were also lower than the -25 mV threshold, indicating a functionally negative charge. In 427 
addition, there were no differences in size, PDI value, or zeta potential upon the loading of 428 
CUR on the NP core, indicating that the loading of the model drug had no significant effect 429 
on the particle systems with respect to these characteristics. 430 
CUR was encapsulated in the NP for two purposes: 1) to provide a model small 431 
molecule that is easy to encapsulate owing to its hydrophobicity and 2) the inherent 432 
fluorescence of CUR within the NP allows for easy fluorescence imaging and detection. 433 
The encapsulation efficiency (EE) of CUR in the NP was lower than previously reported 434 
values, which have ranged from 50-88% [7,9,38]. However, since CUR was used as a 435 
model small molecule, the EE values were satisfactory for this study. Upon coating the NP 436 
with DPPS, CUR loading decreased slightly but the encapsulation efficiency stayed the 437 
same, indicating that the DPPS coating did not significantly affect CUR loading. 438 
The SEM and TEM micrographs indicate that the particles are spherical in shape 439 
and monodisperse, which correlates to the PDI values for the systems. The DPPS-CUR NP 440 
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seem to have slightly more coating on the NP surfaces, which could be due to the increased 441 
presence of DPPS.  442 
 443 
Coating Quantification 444 
DPPS was selected to coat the nanoparticles owing to its ability to stimulate an 445 
“eat-me” signal on apoptotic cells [1,3,11,16,17]. For cell studies, DPPC-NP were 446 
produced as a control lipid system. Initially, the NP systems were coated with PVA because 447 
it is one of the most widely used polymers in the pharmaceutical industry [45] and has been 448 
extensively used as a NP coating agent due to the steric effects PVA coating imparts on 449 
NP, inhibiting aggregation. During the synthesis of phospholipid-coated NP, a significant 450 
portion of the PVA was washed away prior to phospholipid coating, since there is 451 
significantly less PVA present on phospholipid-coated NP in comparison to PVA NP 452 
(Figure 2). It is also likely that the phospholipid coating shielded the remaining PVA upon 453 
adsorption to the NP surface, as indicated by the low mass presence of PVA on 454 
phospholipid-coated NP the high mass presence of total phospholipid on the NP, and the 455 
changes in surface charge (Figure 2).   456 
 457 
Thermal Analysis of Nanoparticle Formulations 458 
 Dry-state DSC thermograms indicated the presence of DPPS in the DPPS-coated 459 
NP via the bilayer phase transition peak that occurred at 90C for the NP, which is slightly 460 
lower than the raw DPPS endothermic peak present at 99C. This transition signifies the 461 
presence of bilayer formation of the phospholipid around the Ac-Dex polymer core in its 462 
dry state. The decrease in the transition temperature is likely due to the interaction of the 463 
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multiple components in the formulation. As the transition temperatures of the NP 464 
formulations were just below or well above 100C, they are likely to be stable in the dry 465 
state and can be easily reconstituted before use [53]. The endothermic peak that raw CUR 466 
exhibited at 177C was not observed in CUR-loaded NP. According to our previous 467 
research (data not shown), this is likely due a limitation in DSC detection with relation to 468 
the actual amount of CUR in the samples.  469 
In studies using liposomal formulations, DSC is used to assess the transition 470 
temperature(s) in the systems in order to determine the presence and state of bilayers and 471 
the differences associated between blank liposomes and modified/drug-loaded systems 472 
[43,44]. For wet-state analysis (Figure 3C), there was no endothermic peak present around 473 
50-60C, which is the temperature at which the gel/crystalline phase transition occurs for 474 
PS bilayers in aqueous solutions [24,54]. Such a phenomenon could have occurred based 475 
on the preparation method used, as described previously. In certain cases, self-assembly of 476 
polymer-lipid structures can occur via hydrophobic interaction between the lipid tails and 477 
a polymeric core simultaneously with hydrophilic interactions between the polar head and 478 
external environment [55]. Due to the concentration dependency of DSC, it is more likely 479 
that the DPPS concentration may have been too low to be detectable by thermal analysis, 480 
like that of the CUR detection limit mentioned previously. It should be noted that the 481 
curvature of the thermograms in Figure 3C corresponds to the evaporation of water, which 482 
is not shown in the thermogram. Overall, the results indicate the presence of DPPS on the 483 
surface of the NP, further strengthening what has been previously described with respect 484 
to successful DPPS coating of the described systems. 485 
 486 
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Curcumin Release from Nanoparticles 487 
The release from CUR from PVA- and DPPS-coated NP was evaluated to 488 
demonstrate the ability of the system to provide sustained release of a therapeutic agent 489 
and to show the acid-sensitive nature of Ac-Dex. Ac-Dex is known to degrade more quickly 490 
in acidic environments [32]. In a previous study, Ac-Dex particles released 60% of their 491 
camptothecin payload after 7 days [35] and 15% of rapamycin after 10 days [4] at pH of 492 
7.4. Comparatively, at pH values of 5 or lower, Ac-Dex particles released 100% of their 493 
content in as little as 24 hours [4,30,33]. For this study, at pH 5.35, 9.3% of CUR was 494 
initially released from DPPS-CUR NP and 29.2% was released after 1 hour, followed by a 495 
sustained release of cargo of 67.8% after 24 hours, when equilibrium is reached. At pH 7.4, 496 
both NP systems exhibited minimal CUR release, demonstrating the stability of Ac-Dex in 497 
neutral pH. However, both systems exhibited triggered release at pH 5.35, exhibiting a 498 
significantly higher total release in comparison to their pH 7.4 counterparts (p < 0.001). 499 
Overall, these data indicate a more stable NP formulation at pH 7.4 and the potential for 500 
triggered release at pH 5.35, corresponding to stability in circulation and burst release in 501 
macrophages, respectively.  502 
 503 
Cytotoxic Analysis and Macrophage Uptake of Nanoparticles 504 
 To assess the in vitro cytotoxicity of the NP formulations on RAW 264.7 505 
macrophages, the cells were exposed to the systems for 48 hours. It was observed that the 506 
NP systems were not toxic to the cells, however, a slight, but significant, decrease in 507 
viability of RAW 264.7 cells for DPPS-CUR NP at 0.2 mg/ml was observed (Figure 5). 508 
This decrease in viability was minimal and could easily be overcome by using lower 509 
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concentrations of the particles in future studies. Overall, these results indicate the safety of 510 
the described NP for a time period longer than necessary for NP uptake into macrophages, 511 
indicating that they are safe to use in the intended fashion. 512 
  Nanomaterials may provoke immune and inflammation responses following 513 
interactions with multiple biological entities [49]. To assess inflammatory and immune 514 
response stimulation, NO production was measured using a Griess assay, where LPS was 515 
used as a positive control to stimulate NO production in RAW macrophages. It was 516 
observed that NP at varying concentrations stimulated significantly less NO production in 517 
comparison to LPS and resulted in NO concentrations comparable to that of the control 518 
(media only). Results indicated that blank NP caused NO production at concentrations 519 
similar to that of the CUR-loaded NP. These data indicate both blank and CUR-loaded 520 
formulations produced minimal NO and that CUR did not play an active role in the 521 
inhibition of NO production.  522 
Since the purpose of this study was to formulate acid-sensitive NP capable of 523 
enhanced macrophage uptake, the ability of DPPS-coated NP to be uptaken by 524 
macrophages was evaluated, with A549 cells acting as control tissue. PVA and DPPC-525 
coated NP were used as other coatings for comparison to DPPS. Several environmental 526 
and physicochemical factors are known to influence the cellular uptake of NP into 527 
macrophages. The preferential uptake of DPPS-CUR NP by macrophages in comparison 528 
to PVA-CUR NP and DPPC-CUR NP is likely due to the DPPS coating on the Ac-Dex 529 
polymeric core. Confocal microscopy in tandem with fluorescence quantification of CUR-530 
loaded NP within the cells confirm the uptake of DPPS-CUR-NP and localization to the 531 
cytoplasm of macrophages. The presence of DPPS on the cellular surface is known to cause 532 
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an “eat-me” signal in cells that are transitioning toward an apoptotic state, causing 533 
macrophages to identify and phagocytose the dying cells [1–3,7,11]. Therefore, in terms of 534 
recognition, the DPPS coating on the Ac-Dex NP was identified by the macrophages, 535 
which produced the necessary phagocytotic action, resulting in cellular uptake of the 536 
particles [1,6,7,16,25,27]. In most cases, apoptosis is initiated by the presence DPPS and 537 
other signaling pathways such as receptor-ligand interactions or identification of PS 538 
binding proteins produced by phagocytes. However, there is a debate as to whether DPPS 539 
recognition by itself is sufficient for the uptake of apoptotic cells by phagocytotic cells 540 
[3,25]. In the case of nanoparticles, is has been shown that a DPPS coating alone is 541 
sufficient for uptake, as seen in this current study and otherwise [7,16,17].  542 
Another consideration for cellular uptake of the described particles is in terms of 543 
their physicochemical characteristics. Stimulation of phagocytosis of nanoparticle-based 544 
delivery systems via macrophages is also dependent on the size and shape of the particles. 545 
Since the DPPS-CUR NP were greater than 300 nm in diameter, it is likely that these NP 546 
were phagocytosed not only because of the DPPS layer, but also because of their size 547 
[4,48,56]. It is well known that surface charge can play a role in biological interactions. 548 
Interestingly, surface charge did not play a role in the uptake of the NP, as shown by the 549 
similar charges of DPPC and DPPS-coated NP that produced significantly different uptake 550 
quantities [48,51,52]. This phenomenon could also explain the minimal phagocytosis of 551 
the PVA-coated NP and confirm the effect of DPPS on the uptake of the NP. Overall, the 552 
results indicate the successful uptake of DPPS-coated NP into macrophages, indicating that 553 
these systems could be used for the treatment of a multitude of diseases involving infected 554 
cells.  555 
 - 25 - 
 556 
Conclusions 557 
Macrophages can harbor infectious agents that lead to potentially fatal diseases 558 
such as TB and HIV. Due to this, treatment of these diseases is challenging and therefore, 559 
the goal of this study was to design a delivery system that would enhance the uptake of 560 
nanoparticles into macrophages, allowing for targeted delivery, a decrease of systemic side 561 
effects, and decreased treatment times. Results showed that both PVA-coated and DPPS-562 
coated NP were monodisperse and that there was a significant increase in size upon DPPS 563 
coating. The surface charge of the DPPS NP was -40 mV, indicating that DPPS was present 564 
on the surface of the NP. This was further confirmed via PVA quantification, which 565 
indicated minimal amounts of PVA on the DPPS NP. DSC results confirmed the presence 566 
of a DPPS bilayer on the NP surface and the likely stability of the NP during synthesis and 567 
storage conditions. CUR-loaded NP successfully encapsulated CUR and this agent was 568 
more quickly released in acidic conditions in comparison to neutral pH owing to the acid 569 
sensitivity of Ac-Dex. In addition, CUR-loaded NP exhibited sustained release of CUR. 570 
PVA-coated NP were not readily phagocytosed by macrophages, whereas DPPS-coated 571 
NP were phagocytosed within 1 hour of exposure, showing the physiological relevance of 572 
the DPPS coating for the enhanced delivery to macrophages. These data show that the 573 
particles can potentially deliver therapeutic agents throughout the body with fewer 574 
concerns of systemic drug exposure, and when exposed to macrophages, the particles are 575 
capable of being phagocytosed relatively quickly. Therefore, the combination of Ac-Dex 576 
and DPPS can be a viable option for targeted delivery for macrophage-associated diseases.  577 
 578 
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Table 1. Diameter, polydispersity index (PDI), surface charge via zeta potential, 601 














PVA-Blank NP 262.6 ± 1.9 0.04 ± 0.00 -2.2 ± 3.5 --- --- 
PVA-CUR NP 272.6 ± 10.4 0.04 ± 0.01 -3.0 ± 0.6 25.1 ± 0.1 7.1 ± 1.8 
DPPS-Blank NP 335.6 ± 3.8 0.21 ± 0.43 -40.4 ± 3.3 --- --- 
DPPS-CUR NP 350.5 ± 16.9 0.13 ± 0.65 -40.6 ± 1.3 24.5 ± 0.1 5.2 ± 0.7 
 603 
 604 
Figure 1. Representative SEM (left) and TEM (middle, right) micrographs of PVA- and 605 
DPPS-coated, CUR-loaded nanoparticles (PVA-CUR NP and PVA-DPPS NP, 606 
respectively).  607 
 608 
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 609 
Figure 2. Quantification of the amount of poly(vinyl alcohol) (PVA) and total 610 
phospholipid in PVA-CUR, DPPC-CUR, and DPPS-CUR nanoparticles (NP) (* p < 0.05, 611 
**p < 0.01,***p < 0.001 in comparison to PVA-CUR NP). 612 
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 613 
Figure 3. Differential scanning calorimetry (DSC) thermograms of: (A) formulated 614 
nanoparticles and (B) the raw components that make up the nanoparticle systems in their 615 
dry state, and (C) formulated nanoparticles in their wet state.  616 
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 617 
Figure 4. Cumulative release of curcumin (CUR) from nanoparticle systems at pH 7 and 618 
pH 5 (*p < 0.05, **p < 0.01, ***p < 0.001, ns = non-significant).   619 
 620 
 621 
Figure 5. Cytotoxicity analysis (relative viability) of nanoparticle systems on RAW 622 
264.7 macrophages after 48 hours of exposure compared to control (*p < 0.05). 623 
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 624 
Figure 6. Nitric oxide (NO) production from RAW 264.7 macrophages incubated for 48 625 
hours with varying concentrations of nanoparticle formulations or LPS. No statistical 626 
significance was observed between the groups and control group (no treatment) and all 627 
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 634 
Figure 7. (Left) Fluorescence spectroscopy analysis of nanoparticle uptake into cells and 635 
(Right) representative confocal images of nanoparticle uptake by RAW 264.7 macrophages 636 
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